Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
Year-over-year operating cash flow growth rate
| Period | Value |
|---|---|
| Q4 2025 | -33.99% |
| Q3 2025 | -48.36% |
| Q2 2025 | 26.97% |
| Q1 2025 | -21.66% |
| Q4 2024 | 11.13% |
| Q3 2024 | -75.48% |
| Q2 2024 | -34.36% |
| Q1 2024 | -11.43% |
| Q4 2023 | -1.55% |
| Q3 2023 | -24.92% |
| Q2 2023 | 2.46% |
| Q1 2023 | -13.17% |
| Q4 2022 | -13.51% |
| Q3 2022 | 21.48% |
| Q2 2022 | 0.62% |
| Q1 2022 | 4.86% |
| Q4 2021 | 35.09% |
| Q3 2021 | -13.14% |
| Q2 2021 | 3.78% |
| Q1 2021 | -13.69% |
| Q4 2020 | 12.16% |
| Q3 2020 | 8.01% |
| Q2 2020 | -36.74% |
| Q1 2020 | -12.77% |
| Q4 2019 | -35.86% |
| Q3 2019 | -84.86% |
| Q2 2019 | 45.83% |
| Q1 2019 | 84.79% |
| Q4 2018 | -192.31% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | -213.58% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | -165.76% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |
| Q2 2016 | 0.00% |
| Q1 2016 | 63.35% |